Funding for this research was provided by:
The EMPA-REG OUTCOME trial was funded by the Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance
Received: 19 January 2018
Accepted: 27 April 2018
First Online: 19 May 2018
Duality of interest
: SV has received research grants and/or speaking honoraria from Boehringer Ingelheim, Eli Lilly, AstraZeneca, Janssen, Merck, Amgen, Sanofi, Valeant, Bayer, Pfizer and Valeant, holds a tier 1 Canada Research Chair, is national lead investigator for the DAPA-HF trial (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients with Chronic Heart Failure), the EMPagliflozin outcomE tRial in Patients With chrOnic heaRt failure with Reduced ejection fraction (EMPEROR-Reduced) and the EMPagliflozin outcomE tRial in Patients With chrOnic heaRt failure with Preserved ejection fraction (EMPEROR-Preserved), and is a member of the steering committees of the Cardiovascular Inflammation Reduction Trial (CIRT) and the Behavior of Valve Leaflets (BELIEVE) trial. CDM has received consulting fees from Amgen, Boehringer Ingelheim and OctaPharma. DF reports honoraria from Sanofi, Merck & Co., Amgen, AstraZeneca, Eli Lilly and Company and Boehringer Ingelheim. SEI has consulted for Janssen, vTv Therapeutics and Alere, served on Clinical Trial Steering/Executive Committees for Boehringer Ingelheim, AstraZeneca, Novo Nordisk, Sanofi/Lexicon Pharmaceuticals, Daiichi-Sankyo and Eisai (Thrombolysis in Myocardial Infarction [TIMI]) and served on Data Monitoring Committees for Intarcia Therapeutics, Inc. BZ has received research grants awarded to his institution from Boehringer Ingelheim, AstraZeneca and Novo Nordisk, and honoraria from Janssen, Sanofi, Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk and Merck. EP and JTG are employees of Boehringer Ingelheim.